Tempest Therapeutics Return on Equity

Tempest Therapeutics (TPST) currently reports a ROE of 3713.03%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Tempest Therapeutics's ROE history and peer comparisons.

Tempest Therapeutics's ROE of 3713.03% is higher than the Healthcare sector average of 11.15%. That is roughly 33188.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Tempest Therapeutics's current 3713.03% should be judged against Healthcare norms (sector average: 11.15%) and against TPST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 3713.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Tempest Therapeutics, and consider following TPST for alerts when major investors trade the stock.

Tempest Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 3713.03% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TPST with unrelated industries.